GCP
CUE icon

GSA Capital Partners’s Cue Biopharma CUE Stock Holding History

GSA Capital Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-678
Closed -$5K – 1813
2026
Q1 		$5K Buy
+678
New +$6.33K ﹤0.01% 1663
2025
Q2 		– Sell
-3,909
Closed -$107K – 1803
2025
Q1 		$107K Sell
3,909
-1,084
-22% -$40.3K 0.01% 1488
2024
Q4 		$163K Sell
4,993
-4,729
-49% -$178K 0.01% 1459
2024
Q3 		$221K Buy
9,722
+470
+5% +$10.2K 0.02% 1376
2024
Q2 		$344K Buy
9,252
+2,282
+33% +$113K 0.02% 1193
2024
Q1 		$395K Buy
6,970
+6,505
+1,399% +$459K 0.03% 1045
2023
Q4 		$37K Buy
+465
New +$33.2K ﹤0.01% 1426
2023
Q3 		– Sell
-609
Closed -$67K – 1560
2023
Q2 		$67K Sell
609
-1,828
-75% -$215K 0.01% 1408
2023
Q1 		$261K Sell
2,437
-3,840
-61% -$366K 0.03% 1110
2022
Q4 		$537K Sell
6,277
-931
-13% -$85.1K 0.07% 561
2022
Q3 		$482K Buy
7,208
+2,886
+67% +$248K 0.06% 592
2022
Q2 		$323K Buy
4,322
+1,103
+34% +$129K 0.05% 776
2022
Q1 		$471K Sell
3,219
-108
-3% -$22.9K 0.06% 575
2021
Q4 		$1.13M Sell
3,327
-731
-18% -$283K 0.14% 151
2021
Q3 		$1.77M Buy
4,058
+3,111
+329% +$1.09M 0.18% 88
2021
Q2 		$331K Buy
947
+525
+124% +$203K 0.04% 890
2021
Q1 		$155K Sell
422
-1,721
-80% -$708K 0.03% 951
2020
Q4 		$804K Buy
2,143
+650
+44% +$260K 0.13% 196
2020
Q3 		$674K Buy
+1,493
New +$860K 0.11% 249

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

GSA Capital Partners's CUE Position: Q2 2026 in Review

GSA Capital Partners sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 678 shares — an estimated $5K sold.

GSA Capital Partners first reported a position in CUE in Q3 2020 and held it in 19 quarters. The position peaked at $1.77M in Q3 2021. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • GSA Capital Partners reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 678 Cue Biopharma shares in Q2 2026, an estimated $5K.
  • GSA Capital Partners first reported a position in Cue Biopharma in Q3 2020 and held it in 19 quarters.
  • GSA Capital Partners's Cue Biopharma position peaked at $1.77M in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.